Cannabis Stocks Are Heating Up Again. Here's Which Ones Could be the Biggest Winners.

Federal marijuana rescheduling and the potential rollback of 280E are improving fundamentals for large cannabis MSOs, with Trulieve and Curaleaf already posting profits in Q1. Trulieve reported $287 million in revenue and $2.4 million in net income, while Curaleaf posted $324 million in revenue and $69.8 million in net income. The article argues that further regulatory progress could boost free cash flow and support eventual major exchange uplistings, a constructive catalyst for the sector.

Analysis

The market is treating this as a clean tax-cut story, but the more important second-order effect is balance-sheet repair. If 280E relief persists, the winners are not the highest-growth operators but the firms with enough scale, cash generation, and tax-loss carryforward complexity to turn incremental pre-tax margin into real equity value; smaller operators without operating leverage may see less benefit because price competition will force much of the tax savings back to consumers.

The big near-term catalyst is not the rescheduling itself but the legal and administrative path that determines whether relief is retrospective, prospective, or partially reversed. That makes this a tape-driven trade over the next 4-8 weeks, with a larger re-rating only if hearings broaden the rule change beyond medical and if debt markets start to price cannabis names as refinanceable credits rather than distressed equities.

The crowd is likely underestimating how much of the upside has already been pulled forward by the recent squeeze. After a sharp three-month move, the risk/reward is less compelling on outright longs unless there is a follow-through catalyst; the better setup is relative value within the sector and option structures that monetize volatility around the June/July hearing window. The real medium-term upside is an eventual institutionalization event: any credible path to uplisting would matter more than one quarter of earnings relief because it changes the shareholder base and lowers the cost of capital.

Contrarian read: the headline is bullish, but the market may be over-anchoring on tax savings while ignoring that federal classification remains politically reversible and operationally uneven across states. In particular, the strongest franchises are the ones with dense local footprints and better compliance infrastructure, not necessarily the names with the biggest national maps; that favors selective ownership over a basket approach.

Key Decisions for Investors

• Long Trulieve vs. a weaker MSO peer basket on a 1-3 month horizon: prefer the name with the best local density and cash conversion, as tax relief should flow most efficiently into free cash flow rather than pricing power.
• Buy near-dated call spreads in Curaleaf into the June 29-July hearing window to express upside with defined risk; the setup is favorable if the market keeps repricing regulatory odds upward, but implied volatility should be capped with spreads.
• Trim outright long exposure in both names into further strength over the next 2-4 weeks; the move has likely front-run part of the policy benefit, and a headline setback could easily mean a 15-20% retracement.
• Look for a credit-oriented long in the stronger MSO and avoid levered balance sheets elsewhere; the key beneficiary of 280E normalization should be lower refinancing costs, so equity upside is best expressed where debt markets can also re-rate.
• If you want sector exposure, use a pair trade: long the best-capitalized, highest-density operator / short a smaller, less efficient MSO to isolate policy beta from operating execution risk.